Atsena Therapeutics has named internist/cardiologist Dr. Kenji Fujita chief medical officer, a new position at the company. He arrives from Alnylam Pharmaceuticals, where he served as VP of clinical development, and held positions at Alexion Pharmaceuticals and Merck prior to that. “His extensive experience leading clinical development programs and executing regulatory strategies will be invaluable as we continue to develop cutting-edge gene therapies with the goal of overcoming the unique hurdles of inherited retinal diseases to prevent or reverse blindness,” said Atsena CEO Patrick Ritschel in a statement.